We are live on ! Find out more
EFTR

eFFECTOR Therapeutics, Inc. Common Stock
EFTR

Delisted

EFTR was delisted on the 2nd of July, 2024.

Back to rankings

12 hedge funds and large institutions have $188M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

62% more capital invested

Capital invested by funds: $116M → $188M (+$72.1M)

79% less funds holding

Funds holding: 58 → 12 (-46)

84% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 55

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
12
Holders Change
-46
Holders Change %
-79.31%
% of All Funds
0.21%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
9
Increased
–
Reduced
3
Closed
55
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
+$62.2M
2
CG
Column Group
California
+$55.6M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$37.2M
4
Blackstone Inc
Blackstone Inc
New York
+$16.9M
5
Verition Fund Management
Verition Fund Management
Connecticut
+$318K

Top Sellers

Rank Fund Capital Flow
1
ECP
Empyrean Capital Partners
California
-$9.89M
2
LA
Linden Advisors
New York
-$8.99M
3
AC
Aristeia Capital
Connecticut
-$8.54M
4
Citadel Advisors
Citadel Advisors
Florida
-$7.62M
5
PAMP
Polar Asset Management Partners
Ontario, Canada
-$4.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
LP
26
LMR Partners
United Kingdom
– -$3.02M -12,199 Closed
ACA
27
Arena Capital Advisors
California
– -$3M -12,138 Closed
FTCM
28
Fir Tree Capital Management
New York
– -$2.97M -12,000 Closed
HIM
29
HGC Investment Management
Ontario, Canada
– -$2.97M -12,000 Closed
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
– -$2.63M -10,628 Closed
Millennium Management
31
Millennium Management
New York
– -$2.54M -10,295 Closed
CH
32
CVI Holdings
Delaware
– -$1.98M -8,000 Closed
PSAMP
33
P. Schoenfeld Asset Management (PSAM)
New York
– -$1.98M -8,000 Closed
SCC
34
Spring Creek Capital
Kansas
– -$1.98M -8,000 Closed
BCM
35
Beryl Capital Management
California
– -$1.73M -6,997 Closed
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
– -$1.65M -6,674 Closed
SCM
37
Saba Capital Management
New York
– -$1.65M -6,656 Closed
Marshall Wace
38
Marshall Wace
United Kingdom
– -$1.5M -6,068 Closed
KIM
39
Karpus Investment Management
New York
– -$1.34M -5,406 Closed
AA
40
AQR Arbitrage
Connecticut
– -$1.33M -5,400 Closed
MP
41
Mangrove Partners
Connecticut
– -$1.25M -5,044 Closed
Alyeska Investment Group
42
Alyeska Investment Group
Illinois
– -$989K -4,000 Closed
PMAM
43
Picton Mahoney Asset Management
Ontario, Canada
– -$990K -4,000 Closed
TCM
44
Tenor Capital Management
New York
– -$989K -4,000 Closed
WA
45
Whitebox Advisors
Minnesota
– -$989K -4,000 Closed
BCM
46
Basso Capital Management
Connecticut
– -$981K -3,967 Closed
ACM
47
Atalaya Capital Management
New York
– -$967K -3,912 Closed
MIG
48
Mariner Investment Group
New York
– -$898K -3,633 Closed
LCM
49
Landscape Capital Management
New Jersey
– -$835K -3,378 Closed
EAM
50
Exos Asset Management
New York
– -$593K -2,400 Closed
1
2
3

EFTR Hedge Fund Activity: Q3 2021 in Review

12 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q3 2021, worth a combined $188M — up 62% from $116M a quarter earlier.

Sellers outnumbered buyers: 55 funds closed out of EFTR and 9 opened new positions — a net loss of 46 holders — while 3 trimmed existing stakes and 0 added.

The largest buyer was Abingworth, opening a new position worth an estimated $62.2M. The largest seller was Empyrean Capital Partners, exiting entirely with an estimated $9.89M sold.

  • 12 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q3 2021, down from 58 in Q2 2021.
  • Funds reported $188M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q3 2021, up 62% quarter-over-quarter.
  • 9 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q3 2021 and 55 closed out, a net change of -46 holders.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q3 2021 was Abingworth, an estimated $62.2M added.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q3 2021 was Empyrean Capital Partners, an estimated $9.89M sold.

Based on aggregated 13F filings for Q3 2021.